ReviewSeminars in radiation oncology2021
The Role of Theranostics in Prostate Cancer.
Review in Seminars in radiation oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 34 citations in OpenAlex.
- Diagnostic Twins: Exploring the Radiohybrid Concept with Iodine-123 and Lanthanum-133 for PSMA-Targeted SPECT and PET Imaging.Journal of medicinal chemistry · 2026Article
- Synthesis of DOTA-BasedMethods and protocols · 2025Article
- Article
- Future Prospect of Low-Molecular-Weight Prostate-Specific Membrane Antigen Radioisotopes Labeled as Theranostic Agents for Metastatic Castration-Resistant Prostate Cancer.Molecules (Basel, Switzerland) · 2024Review
- Theranostics Nuclear Medicine in Prostate Cancer.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Lutetium-177 Labelled Anti-PSMA Monoclonal Antibody (Lu-TLX591) Therapy for Metastatic Prostate Cancer: Treatment Toxicity and Outcomes.Molecular diagnosis & therapy · 2024Article
- Emerging Role of Nuclear Medicine in Prostate Cancer: Current State and Future Perspectives.Cancers · 2023Review
- Accelerator-Based Production of Scandium Radioisotopes for Applications in Prostate Cancer: Toward Building a Pipeline for Rapid Development of Novel Theranostics.Molecules (Basel, Switzerland) · 2023Article
- Ultrastructural Analysis of Cancer Cells Treated with the Radiopharmaceutical Radium Dichloride ([Cells · 2023Article
- GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches.Frontiers in oncology · 2023Article
- Theragnostic Radionuclide Pairs for Prostate Cancer Management:Biomedicines · 2022Review
- Site-Specific Intact N-Linked Glycopeptide Characterization of Prostate-Specific Membrane Antigen from Metastatic Prostate Cancer Cells.ACS omega · 2022Article
- An ImprovedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- PSMA Theranostics: Current Landscape and Future Outlook.Cancers · 2021Review
- S100A14 inhibits cell growth and epithelial-mesenchymal transition (EMT) in prostate cancer through FAT1-mediated Hippo signaling pathway.Human cell · 2021Article
- Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome afterDiagnostics (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Theranostics in men with metastatic castration-resistant prostate cancer (mCRPC) has been developed to target bone and the tumor itself. Currently, bone-directed targeted alpha therapy with radium-223 (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.